NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 11894.25 -1.20 -0.01%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

iBio, Inc. (AMEX: IBIO)

 
IBIO Technical Analysis
4
As on 31st Oct 2017 IBIO Share Price closed @ 0.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.37 & Sell for SHORT-TERM with Stoploss of 0.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

IBIO Share Price

Open 0.31 Change Price %
High 0.31 1 Day -0.01 -3.23
Low 0.30 1 Week 0.00 0.00
Close 0.30 1 Month 0.00 0.00
Volume 186287 1 Year -0.16 -34.78
52 Week High 0.56 | 52 Week Low 0.26
 
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
NGD 3.29 -6.80%
RBY 0.03 -70.00%
LODE 0.12 -7.69%
PBTH 8.23 0.37%
GGR 0.02 100.00%
VTG 0.05 -16.67%
SYRG 8.13 0.87%
GSX 0.02 0.00%
SHZ 0.10 -16.67%
 
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
 
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
LBY 6.84 -25.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
 
 
IBIO
Daily Charts
IBIO
Intraday Charts
Whats New @
Bazaartrend
IBIO
Free Analysis
 
IBIO Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE0.31
RESISTANCE0.31
SUPPORT0.29
SUPPORT0.29
SUPPORT0.00
SUPPORT0.00
 
IBIO Target for Month November
4th UP TARGET0.49
3rd UP TARGET0.43
2nd UP TARGET0.39
1st UP TARGET0.35
1st DOWN TARGET0.25
2nd DOWN TARGET0.21
3rd DOWN TARGET0.17
4th DOWN TARGET0.11
 
IBIO Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
IBIO Target for Year 2019
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
IBIO Other Details
Segment EQ
Market Capital 43945728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ibioinc.com
 
IBIO Address
IBIO
9 Innovation Way
Suite 100
Newark, DE 19711
United States
Phone: 302-355-0650
 
IBIO Latest News
 
Your Comments and Response on iBio, Inc.
 
IBIO Business Profile
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service